

**Anti-von Willebrand factor (human, vWf)****Mouse monoclonal antibody**Subclass: IgG<sub>1</sub>/k

CAT. NO.

**HYB 060-01**

Clone: 5E7

---

**SPECIFICITY** HYB 060-01 is specific for human vWf from human serum or plasma.**IMMUNOGEN** Factor VIII complex isolated from human plasma**TESTED APPLICATIONS** ELISA**SPECIES REACTIVITY (POSITIVE)** Human**SPECIES REACTIVITY (NEGATIVE)** Not determined**EPITOPE SPECIFICITY** Epitope specificity differs from that of HYB 060-02

---

**PRESENTATION****Content:** Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.**Preparation:** Protein-A purified**Form:** Liquid**Solvent:** 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide**Storage:** 4-8°C without exposure to light. No precautions necessary during handling.

---

**APPLICATION** **ELISA:** HYB 060-01 reacts strongly with vWf. A strong reaction is seen in ELISA with vWf directly coated onto the microtiterplate, and also when used in sandwich ELISA in combination with a polyclonal antibody against the antigen (e.g. DAKO A082).**TARGET** Von Willebrand factor (vWf) is a series of self-aggregated structures, all derived from common glycoprotein subunits, synthesized in endothelial cells and megakaryocytes. The molecular mass of the monomeric vWf unit is 225 kDa. vWf binds to circulating factor VIIIc (antihemophilic factor), hereby stabilizing the latter thus being an important factor in the normal primary haemostasis.**REFERENCES****CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.